Docoh
Loading...

CCEL Cryo-Cell International

Filed: 19 Jul 21, 5:00pm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2021

 

CRYO-CELL INTERNATIONAL, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

0-23386

22-3023093

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

700 Brooker Creek Blvd., Suite 1800, Oldsmar, FL

 

34677

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (813) 749-2100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, Par Value $0.01

 

CCEL

 

OTCQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 


 

 

 

Item 2.02.

Results of Operations and Financial Condition.

On July 15, 2021, Cryo-Cell International, Inc. (the "Registrant") issued the attached Press Release reporting on financial results for the three months ended May 31, 2021.  The press release giving details associated with the Registrant's earnings is attached as Exhibit 99.1 to this report.  The information included in Exhibit 99.1 is considered to be "furnished" under the Securities Exchange Act of 1934.

 

Item 9.01. Financial Statements and Exhibits.

 

Financial Statements of Businesses Acquired

Not Applicable

 

Pro Forma Financial Information

Not Applicable

 

Shell Company Transactions

Not Applicable

 

Exhibits

 

 

Exhibit No.

Description

 

99.1

Press Release, dated July 15, 2021

 

104

Cover Page Interactive Data File – the cover page iXBRL tags are embedded within the Inline XBRL document

 

 


 


 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

CRYO-CELL INTERNATIONAL, INC.

 

 

 

 

Dated: July 19, 2021

 

 

 

By:

 

/s/ David Portnoy

 

 

 

 

 

 

David Portnoy

 

 

 

 

 

 

Chairman and Co-Chief Executive Officer